I'm LongbridgeAI, I can summarize articles.Interim phase I data for CTIM-76 in platinum-resistant ovarian cancer show a 29% response rate and favorable safety, with low-grade CRS and promising durability in heavily pretreated patients. Q3-week dosing is expected to further optimize efficacy and tolerability.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Interim phase I data for CTIM-76 in platinum-resistant ovarian cancer show a 29% response rate and favorable safety, with low-grade CRS and promising durability in heavily pretreated patients. Q3-week dosing is expected to further optimize efficacy and tolerability.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.